P4 peptide

The term "P4 peptide" refers to at least two distinct experimental peptide therapeutics identified in clinical and preclinical research. One version is a 28-amino-acid synthetic peptide derived from the functional site of the *Streptococcus pneumoniae* pneumococcal surface adhesion A (PsaA) protein. This immunoactivating peptide works by enhancing macrophage phagocytic function and upregulating the killing of pathogens such as *Streptococcus pneumoniae*, MRSA, and influenza-pneumonia coinfections. It is being investigated as a potential treatment for severe pneumonia and sepsis. The second version is a second-generation peptide inhibitor designed to disrupt the cis-dimerization of Junctional Adhesion Molecule-A (JAM-A/F11R). Developed by researchers at the RCSI University of Medicine and Health Sciences, this P4 peptide aims to treat high-risk multiple myeloma by impairing cancer cell proliferation, adhesion to the bone marrow niche, and invasion.

Other names

PsaA-derived P4 peptideJAM-A inhibitor P4